MedTech Strategist, the industry's most trusted resource, will help you stay ahead of the opportunities and obstacles that are impacting your corporate strategy. We invite you to explore our coverage. Think Strategically. Subscribe Today .
Trial Browse Latest Issue
Augmedics was on the way to a round of financing that would fund commercial launch of its augmented reality surgical guidance technology. Then COVID-19 hit. To the rescue: the company’s US employees who helped fill out the most recent round.
Subscribe now to read the full analysis
Automated insulin delivery systems were a highlight of this year’s (virtual) ADA meeting, with presentations on new devices from Medtronic, Tandem Diabetes Care, Insulet, Beta Bionics, and Eli Lilly, all vying for a top spot in this fast-evolving space. Industry analysts opine on their commercial prospects as well as Dexcom and Abbott’s efforts to expand CGM to the type 2 diabetes population.
Subscribe now to read the full analysis
What are the strategic implications for medtech companies as they contemplate the “post-COVID” world? L.E.K. looks at the near-term and longer-term impacts. By Jonas Funk, Monish Rajpal, Ilya Trakhtenberg, and Sheila Shah, L.E.K. Consulting.
Subscribe now to read the full analysis